シンポジウム 12

Patient-derived“sarcoma”models; current
status of NCC-sarcoma model series

Sarcomas are unique mesencyhmal malignancies. Sarcomas consist of more than 50
histological subtypes, which exhibit different molecular features and clinical behaviors, andoccur almost everywhere in human body. Although such complexity and diversity, sarcomas
are rare; they account for less than 1% of all malignancies. Because of these characteristics, thedevelopment of novel therapy for sarcomas is challenging, and the effective anti-cancer drugs
are limited in sarcomas. A lack of adequate cancer models is one of the major reasons whyTadashi Kondo
Division of Rare Cancer ResearchNational Cancer Center Research Institute[Awards]
2010
2009
2007

the clinical study and even basic research is difficult to conduct in sarcomas. Our systematic
review revealed that only 136 cell lines are available from the public cell banks, and the most ofavailable cell lines are derived from a few histological subtypes. Patient-derived xenografts arealso difficult to obtain from any public domains. To address the issue of patient-derived sarcoma
models, we started to establish cell lines and xenografts of sarcomas in 2014. Since then, wechallenged tumor tissues of 300 sarcoma cases. We have presently established 40 each of cellline and xenograft. All established cell lines were published, and delivered upon a request byresearchers. The model establishment cannot be achieved by any single institutes, because ofsample availability and model accessibility. With this notion, we work with many researchers,
doctors and companies outside our institute. We join to the international consortium to establish
and utilize the cancer cell lines. Moreover, to promote the use of sarcoma PDX, we launched acollaboration study with Charles River Laboratories. We will make all our sarcoma PDX models
available in the contract research worldwide. To expand the sarcoma model repertory, welaunched a new collaborative study with the Tochigi Cancer Center, where many patients withsarcomas are treated and provide their tumor tissues for the medical research.
Using the established sarcoma models, we are currently investigating the correlation
between the results of NCC Oncopanel assay and the response to molecular target drugs. The2004

Kodama Memorial Award, Title: Electrophoresis Approach for Biomarker Development Towards
Personalized Medicine, Japanese Electrophoresis Society
Tamiya Memorial Award, Title: Cancer Biomarker Development by Proteomic Approach,Foundation for Promotion of Cancer Research
26th Young Incitement Award, Title: Lung Cancer Proteomics towards Personalized Medicine –Biomarker Development to Predict Response of Recurrent Lung Adenocarcinoma to Gefitinib
Treatment, Japanese Cancer Association
Young Investigator Award, Title: Proteomics of Lymphoid Neoplasms – Proteome-mining for 2D
Gel, Human Proteome Organization[References]
1. Hattori E, Oyama R, Kondo T. Systematic Review of the Current Status of Human Sarcoma Cell Lines.
Cells. 2019 Feb 13;8(2).
2. Kito F, Oyama R, Sakumoto M, Shiozawa K, Qiao Z, Toki S, Yoshida A, Kawai A, Kondo T.
Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with
myxofibrosarcoma. Hum Cell. 2019 Apr;32(2):214-222.
3. Oyama R, Kito F, Takahashi M, Sakumoto M, Shiozawa K, Qiao Z, Noguchi R, Kubo T, Toki S, Nakatani
F, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel dedifferentiatedchondrosarcoma cell line, NCC-dCS1-C1. Hum Cell. 2019 Apr;32(2):202-213.
4. Oyama R, Takahashi M, Kito F, Sakumoto M, Takai Y, Kumiko S, Qiao Z, Toki S, Tanzawa Y,Yoshida A, Kawai A, Kondo T. Establishment and characterization of patient-derived pleomorphic
rhabdomyosarcoma models. Tiss. Cult. Res. Commun. 2019;38(1)1-12.
5. Oyama R, Kito F, Qiao Z, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A, Kondo T.
Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines,
NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell Dev Biol Anim. 2019 Jan;55(1):62-73.

utility and limitation of oncopanel assay have been discussed in the clinical setting, and we aim
to clarify the significance of actionable gene mutations in sarcomas in terms of prediction ofclinical outcome.
All these result and research resources will be shared in the community of researchers in
the near future. Sarcomas are typical rare cancers, and their problems such as scare availabilityof experimental models are common among the other rare cancers. Based on our experience, we
hope to improve the research circumstances of rare cancer research.

42

近藤 格
国立がん研究センター研究所

希少がん研究分野分野長

1992年 岡山大学医学部卒
1996年 岡山大学医学部助手
1998年 ミシガン大学小児血液腫瘍学部門・博士研究員
2000年 岡山大学医学部助手
2001年 （旧）
国立がんセンター研究所・生物学部・室長
腫瘍プロテオミクスプロジェクト・メンバー（併任）2005年 （旧）
国立がんセンター研究所
プロテオーム・バイオインフォマティクス・プロジェクト・リーダー
2010年 独立行政法人国立がん研究センター研究所・創薬プロテオーム研究分野・分野長
2013年 独立行政法人国立がん研究センター中央病院
稀少がん対策室員・トランスレーショナルリサーチ担当（併任）2014年 独立行政法人国立がん研究センター研究所・希少がん研究分野・分野長
創薬標的・シーズ評価部門・部門長（併任）2015年 国立研究開発法人国立がん研究センター
研究所：希少がん研究分野・分野長、創薬標的・シーズ評価部門・部門長（併任）
中央病院：稀少がん対策室・室員（併任）43